$MCRB
Seres Therapeutics, Inc. Stock $mcrb

$mcrb Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000156459021023017 Filed on May 04, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$5.718M	$8.190M
YoY Change	-30.18%	23.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.74M	$6.140M
YoY Change	91.21%	-18.13%
% of Gross Profit
Research & Development	$29.30M	$21.74M
YoY Change	34.79%	-5.02%
% of Gross Profit
Depreciation & Amortization	$1.476M	$1.802M
YoY Change	-18.09%	-10.17%
% of Gross Profit
Operating Expenses	$41.04M	$27.88M
YoY Change	47.21%	-12.53%
Operating Profit	-$35.33M	-$19.69M
YoY Change	79.39%	-19.8%
Interest Expense	$270.0K	-$560.0K
YoY Change	-148.21%	-354.55%
% of Operating Profit
Other Income/Expense, Net	-$139.0K	-$189.0K
YoY Change	-26.46%	-185.91%
Pretax Income	-$35.47M	-$19.88M
YoY Change	78.42%	-18.29%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$35.47M	-$19.88M
YoY Change	78.39%	-18.3%
Net Earnings / Revenue	-620.23%	-242.75%
Basic Earnings Per Share	-$0.39
Diluted Earnings Per Share	-$387.5K	-$280.7K
COMMON SHARES
Basic Shares Outstanding	91.53M	71.07M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$242.8M	$75.10M
YoY Change	223.3%	39.81%
Cash & Equivalents	$66.58M	$54.86M
Short-Term Investments	$176.2M	$20.20M
Other Short-Term Assets	$6.600M	$3.400M
YoY Change	94.12%	-54.67%
Inventory
Prepaid Expenses
Receivables	$2.600M	$2.100M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$252.0M	$80.60M
YoY Change	212.66%	18.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.58M	$28.70M
YoY Change	-52.68%	-24.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$29.70M
YoY Change
Other Assets	$602.0K	$1.400M
YoY Change	-57.0%	-6.67%
Total Long-Term Assets	$53.70M	$30.00M
YoY Change	79.0%	-23.47%
TOTAL ASSETS
Total Short-Term Assets	$252.0M	$80.60M
Total Long-Term Assets	$53.70M	$30.00M
Total Assets	$305.7M	$110.6M
YoY Change	176.4%	3.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.900M	$5.500M
YoY Change	-10.91%	41.03%
Accrued Expenses	$8.100M	$7.000M
YoY Change	15.71%	-12.5%
Deferred Revenue
YoY Change
Short-Term Debt	$3.300M	$0.00
YoY Change
Long-Term Debt Due	$3.300M
YoY Change
Total Short-Term Liabilities	$47.86M	$44.10M
YoY Change	8.53%	6.09%
LONG-TERM LIABILITIES
Long-Term Debt	$21.90M	$24.80M
YoY Change	-11.69%
Other Long-Term Liabilities	$92.30M	$103.4M
YoY Change	-10.74%	15955.9%
Total Long-Term Liabilities	$114.2M	$128.2M
YoY Change	-10.92%	19806.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$47.86M	$44.10M
Total Long-Term Liabilities	$114.2M	$128.2M
Total Liabilities	$162.0M	$172.3M
YoY Change	-5.98%	-2.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$584.2M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$143.7M	-$61.65M
YoY Change
Total Liabilities & Shareholders Equity	$305.7M	$110.6M
YoY Change	176.4%	3.36%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$35.47M	-$19.88M
YoY Change	78.39%	-18.3%
Depreciation, Depletion And Amortization	$1.476M	$1.802M
YoY Change	-18.09%	-10.17%
Cash From Operating Activities	-$29.50M	-$24.25M
YoY Change	21.63%	-25.14%
INVESTING ACTIVITIES
Capital Expenditures	$1.342M	$71.00K
YoY Change	1790.14%	-76.8%
Acquisitions
YoY Change
Other Investing Activities	-$19.40M	$9.500M
YoY Change	-304.21%
Cash From Investing Activities	-$20.74M	$9.437M
YoY Change	-319.75%	-3183.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	764.0K	4.545M
YoY Change	-83.19%	846.88%
NET CHANGE
Cash From Operating Activities	-29.50M	-24.25M
Cash From Investing Activities	-20.74M	9.437M
Cash From Financing Activities	764.0K	4.545M
Net Change In Cash	-49.47M	-10.27M
YoY Change	381.74%	-68.13%
FREE CASH FLOW
Cash From Operating Activities	-$29.50M	-$24.25M
Capital Expenditures	$1.342M	$71.00K
Free Cash Flow	-$30.84M	-$24.32M
YoY Change	26.79%	-25.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M13D
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y29D
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-37465
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4326290
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	200 Sidney Street - 4th Floor
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2021Q1	dei	City Area Code CityAreaCode	617
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	945-9626
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q1	us-gaap	Short Term Investments ShortTermInvestments	176221000
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	91622669
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66579000
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8386000
CY2021Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1400000
CY2021Q1	us-gaap	Long Term Investments LongTermInvestments	29749000
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	602000
CY2020Q4	us-gaap	Assets Assets	342940000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4018000
CY2020Q4	mcrb	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	14226000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5115000
CY2021Q1	us-gaap	Notes Payable Current NotesPayableCurrent	3339000
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	454000
CY2021Q1	mcrb	Contract With Customer Liability Current Related Party ContractWithCustomerLiabilityCurrentRelatedParty	21242000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46415000
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	24639000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10561000
CY2020Q4	mcrb	Contract With Customer Liability Noncurrent Related Party ContractWithCustomerLiabilityNoncurrentRelatedParty	85572000
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15000
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	966000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-548776000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	174750000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	342940000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-35326000
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	49825000
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5250000
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	47863000
CY2021Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	21872000
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9194000
CY2021Q1	mcrb	Contract With Customer Liability Noncurrent Related Party ContractWithCustomerLiabilityNoncurrentRelatedParty	82284000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	91459239
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91459239
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-47000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19881000
CY2020Q1	mcrb	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1066000
CY2021Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	696000
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-409000
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	368000
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-189000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19881000
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	70821514
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	32000
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-10000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	32000
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-10000
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35433000
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19891000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-48324000
CY2020Q1	mcrb	Stock Issued During Period Value At Market Equity Offerings StockIssuedDuringPeriodValueAtMarketEquityOfferings	4178000
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	249000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1959000
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-10000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19881000
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-61649000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	174750000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	372000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-35465000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	143705000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-35465000
CY2021Q1	mcrb	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	655000
CY2020Q1	mcrb	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	536000
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-851000
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	66000
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6634000
CY2021Q1	mcrb	Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities	-1229000
CY2021Q1	mcrb	Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets	-1402000
CY2020Q1	mcrb	Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets	203000
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6783000
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	237000
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4648000
CY2021Q1	mcrb	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1232000
CY2020Q1	mcrb	Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities	-1771000
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29496000
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24251000
CY2021Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	46944000
CY2021Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	27548000
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20738000
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9437000
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	60000
CY2020Q1	mcrb	Proceeds From Issuance Of Common Stock And Restricted Common Stock ProceedsFromIssuanceOfCommonStockAndRestrictedCommonStock	120000
CY2020Q1	mcrb	Proceeds From At The Market Equity Offering Net Of Commissions ProceedsFromAtTheMarketEquityOfferingNetOfCommissions	4116000
CY2021Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	392000
CY2020Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	249000
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4545000
CY2020Q1	mcrb	Unsettled Issuance Of Common Stock From At The Market Offering UnsettledIssuanceOfCommonStockFromAtTheMarketOffering	62000
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	mcrb	Entity Incorporation Month And Year Of Incorporation EntityIncorporationMonthAndYearOfIncorporation	2010-10
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-584241000
CY2021Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	272549000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-35465000
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29496000
CY2021Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	272549000
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. In the condensed consolidated financial statements, the Company uses estimates and assumptions related to revenue recognition and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenue, operating expenses, clinical trials and employee-related amounts, will depend on future developments that are highly uncertain, including new information that may emerge concerning COVID-19 and the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company’s estimates.</p>
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11890589
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10790286
CY2021Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1400000
CY2020Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1400000
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	205985000
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	32000
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	47000
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	205970000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	187439000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	187392000
CY2021Q1	mcrb	Cash Equivalents Original Maturity Maximum Period CashEquivalentsOriginalMaturityMaximumPeriod	P90D
CY2021Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	1400000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	156627000
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1476000
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1802000
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	176213000
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	176221000
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	137588000
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	137567000
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	29772000
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	29749000
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	49851000
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	49825000
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	205985000
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	205970000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	187439000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	187392000
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	49377000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	48217000
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	35797000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	34320000
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13580000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13897000
CY2021Q1	mcrb	Accrued Development And Clinical Manufacturing Costs Current AccruedDevelopmentAndClinicalManufacturingCostsCurrent	8776000
CY2020Q4	mcrb	Accrued Development And Clinical Manufacturing Costs Current AccruedDevelopmentAndClinicalManufacturingCostsCurrent	6339000
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2881000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6734000
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1496000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1153000
CY2021Q1	mcrb	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	13153000
CY2020Q4	mcrb	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	14226000
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	949000
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	11970000
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	12081000
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	25000000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10037130
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1924406
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	104184
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	260973
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11596379
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	122100000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.66
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	37985000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	19.33
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.06
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3624000
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1959000
CY2021Q1	mcrb	Collaborative Arrangement Upfront License Fee Received CollaborativeArrangementUpfrontLicenseFeeReceived	120000000
CY2021Q1	mcrb	Contract With Customer Liability Revenue Recognized With Related Party ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty	4648000
CY2020Q1	mcrb	Contract With Customer Liability Revenue Recognized With Related Party ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty	6634000
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q1	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0

Files In Submission

Name	View Source	Status
0001564590-21-023017-index-headers.html	Edgar Link	pending
0001564590-21-023017-index.html	Edgar Link	pending
0001564590-21-023017.txt	Edgar Link	pending
0001564590-21-023017-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mcrb-10q_20210331.htm	Edgar Link	pending
mcrb-10q_20210331_htm.xml	Edgar Link	completed
mcrb-20210331.xsd	Edgar Link	pending
mcrb-20210331_cal.xml	Edgar Link	unprocessable
mcrb-20210331_def.xml	Edgar Link	unprocessable
mcrb-20210331_lab.xml	Edgar Link	unprocessable
mcrb-20210331_pre.xml	Edgar Link	unprocessable
mcrb-ex311_7.htm	Edgar Link	pending
mcrb-ex312_6.htm	Edgar Link	pending
mcrb-ex321_9.htm	Edgar Link	pending
mcrb-ex322_10.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MCRB
Seres Therapeutics, Inc. Stock $mcrb

2021 Q1 Form 10-Q Financial Statement

#000156459021023017 Filed on May 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MCRB Seres Therapeutics, Inc. Stock $mcrb

2021 Q1 Form 10-Q Financial Statement

#000156459021023017 Filed on May 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MCRB
Seres Therapeutics, Inc. Stock $mcrb